帕金森氏症深部脑部刺激疗法市场：按技术、组件、最终用户和分销管道划分－2025-2032年全球预测

预计到 2032 年，巴金森氏症深部脑部刺激市场规模将达到 40.2 亿美元，复合年增长率为 15.90%。

本书全面介绍了神经调控、多学科临床路径和设备创新的进展如何融合在一起，重新定义帕金森氏症患者的治疗。

深部脑部刺激（DBS）已从一项实验性神经外科技术发展成为帕金森氏症患者的重要治疗方法。本文从临床、技术和系统层面阐述了DBS的当代应用。电极设计、刺激程序设定、影像融合和闭合迴路控制的进步正在改变人们对症状改善、手术流程和长期设备管理的预期。同时，多学科诊疗模式正在革新围手术全期路径，以优化候选患者的筛选、降低併发症发生率并改善术后復健。这些趋势要求医院系统和专科诊所重新思考人员配备、影像处理设备以及神经调控管治，以维持高品质的治疗效果。

随着新功能和自适应技术的涌现，监管互动和支付方参与变得日益重要。製造商和临床倡导者必须清楚地展示其价值，超越症状控制，涵盖生活品质指标、减轻用药负担以及后续医疗资源利用等。供应链韧性和设备服务模式也同样成为营运重点，因为医疗机构正在考虑建立内部电池更换、编程后续追踪、导线管理等服务能力。因此，现代DBS技术的应用不再仅仅被视为一种外科手术设备，而是一个融合了技术、医疗服务和商业策略的综合性临床计画。

本书对当今DBS实践中正在发生的临床通讯协定、设备架构、报销框架和以患者为中心的结果等方面的变革性转变进行了策略性、深入的概述。

DBS（脑深部刺激）领域正在经历一场变革性的转变，这场变革涵盖临床实务、设备设计、健保报销体係以及病患期望等各个面向。临床上，对精心筛选的患者早期疗育的日益重视，促使转诊途径的修订以及运动障碍神经科和功能神经外科医生之间合作的加强。自适应控制模式和改进的电极结构能够实现更个人化的刺激方案，进而影响手术标靶的选择和术后程控策略。这些设备层面的改善正推动临床医师采用包含认知、自主神经和生活品质等领域（而非仅是运动评分）的疗效评估指标。

同时，健保报销和卫生技术评估框架也在不断发展，以纳入真实世界证据和长期疗效数据。这种转变要求製造商和医疗系统共同製定证据产生计划，以证明产品的临床和经济价值。供应链和生产策略正朝着模组化和区域化方向发展，以降低单一来源中断的风险，并加快软体驱动型设备更新的上市速度。远距程式设计、远端医疗医疗追踪和患者报告结果正在加速混合医疗模式的普及。总而言之，这些转变正在重塑竞争动态，并为临床、技术和商业相关人员之间的策略合作创造机会。

对美国关税在2025年对DBS设备供应链、组件采购、采购成本和跨境製造的累积影响进行严格评估

美国2025年关税的实施对深部脑部刺激（DBS）生态系统产生了多方面的影响，包括成本结构、采购决策和生产布局的调整。依赖跨境供应导线、植入式脉衝产生器和辅助组件的製造商面临投入成本上升的困境，这迫使他们重新评估供应商关係和库存策略。为此，一些医疗设备製造商加快了供应链多元化进程，并探索近岸外包方案以降低贸易政策波动带来的风险；而另一些製造商则选择承受短期成本上涨，以维持与医疗系统签订的合约价格。

从采购角度来看，医院和门诊手术中心重新评估了设备选择标准，将整体拥有成本、物流复杂性以及保固和服务安排纳入考量。集团采购组织和联网医疗系统加强了长期服务协议和备件供应的谈判，以管控营运风险。监管和海关审批流程也影响了新产品上市的前置作业时间，促使製造商更早规划应用，并与相关人员进行更积极的沟通。随着时间的推移，关税调整凸显了弹性供应链设计、透明的成本模型以及医疗设备供应商和医疗服务提供者之间协作合约的重要性。

精细化的细分洞察解释了DBS技术、组件、终端用户设定和通路的差异将如何驱动临床应用和商业策略。

精细的细分观点揭示了技术选择、组件架构、临床环境和分销模式如何影响DBS（深部脑部刺激）的普及动态和商业策略。基于技术，市场可分为自适应和传统两大类。自适应细分市场可进一步分为运动回馈和神经回馈，二者在程式设计复杂性、追踪顺序和证据产生要求方面有显着差异。专注于运动回馈的设备往往优先考虑与穿戴式装置和感测器平台的集成，而神经回馈解决方案则需要更先进的讯号处理和闭合迴路检验来证明其临床可靠性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 具有即时神经回馈的封闭回路型自适应刺激系统的出现
• 扩展定向导线技术，以实现更精准的标靶化和症状控制
• 整合人工智慧驱动的程式设计演算法，以优化患者特异性刺激参数
• 发展微创立体定向手术，提升手术精准度
• 可充电植入式脉衝产生器的广泛应用减少了更换手术的次数。
• 用于远端DBS设备监测和非侵入性参数调整的无线遥测技术的进步
• 基于患者表型和生物标记谱的个人化治疗通讯协定的重要性日益凸显。
• 神经科技公司和学术机构合作，共同研发下一代深部脑部刺激技术。
• 加大对旨在缓解非运动症状的缓解疾病神经调控范式的投资
• 新型电极设计获得监管部门核准，实现多触点电流控制功能

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按技术分類的巴金森氏症深部脑部刺激疗法市场

• 自适应
  • 运动回馈
  • 神经回馈
• 传统的

9. 帕金森氏症深部脑部刺激疗法市场（按组件划分）

• 扩张
• 植入式脉衝产生器
• 带领
• 程式设计师

第十章 帕金森氏症深部脑部刺激疗法市场（依最终用户划分）

• 门诊手术中心
• 医院
• 专科诊所

第十一章 帕金森氏症深部脑部刺激疗法市场（依分销管道划分）

• 直销
• 经销合作伙伴网络

12. 各地区帕金森氏症深部脑部刺激疗法市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 帕金森氏症深部脑部刺激疗法市场（以群体划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

14. 各国帕金森氏症深部脑部刺激疗法市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Medtronic plc
  • Boston Scientific Corporation
  • Abbott Laboratories
  • Neurology Solutions
  • Suzhou PINS Medical Co., Ltd.
  • Aleva Neurotherapeutics SA
  • Renishaw plc
  • Newronika Srl
  • LivaNova, plc
  • Inomed Medizintechnik GmbH

The Deep Brain Stimulation in Parkinson's Disease Market is projected to grow by USD 4.02 billion at a CAGR of 15.90% by 2032.

A comprehensive introduction establishing how advances in neuromodulation, multidisciplinary clinical pathways, and device innovation converge to redefine Parkinson's disease patient care

Deep brain stimulation has evolved from an experimental neurosurgical technique into a cornerstone intervention for selected patients with Parkinson's disease, and this introduction frames the contemporary clinical, technological, and system-level context in which DBS operates. Advances in electrode design, stimulation programming, imaging integration, and closed-loop control have altered expectations around symptomatic benefit, procedural workflows, and long-term device management. At the same time, multidisciplinary care models are shifting perioperative pathways to improve candidate selection, reduce complication rates, and optimize postoperative rehabilitation. These trends require hospital systems and specialty clinics to rethink staffing, imaging capacity, and neuromodulation governance to sustain high-quality outcomes.

Regulatory interaction and payer engagement are increasingly important as novel features and adaptive technologies emerge; manufacturers and clinical champions must now articulate value beyond symptom control to include quality-of-life metrics, reductions in medication burden, and downstream healthcare utilization. Supply chain resilience and device servicing models have likewise become operational priorities as institutions weigh in-house capabilities for battery replacements, programming follow-ups, and lead management. As a result, the contemporary introduction positions DBS not merely as a surgical device but as an integrated clinical program that intersects technology, care delivery, and commercial strategy.

An in-depth strategic overview of transformative shifts in clinical protocols, device architecture, reimbursement frameworks, and patient-centered outcomes shaping DBS practice today

The DBS landscape is undergoing transformative shifts that span clinical practice, device engineering, reimbursement ecosystems, and patient expectations. Clinically, greater emphasis on earlier intervention for well-selected patients is prompting revised referral pathways and heightened collaboration between movement disorder neurologists and functional neurosurgeons. Technological innovation has reinforced this shift: adaptive control paradigms and improved lead architectures are enabling more personalized stimulation profiles, which in turn influence surgical targeting and postoperative programming strategies. These device-level improvements are prompting clinicians to adopt outcome measures that extend beyond motor scores to incorporate cognitive, autonomic, and quality-of-life domains.

Concurrently, reimbursement and health technology assessment frameworks are evolving to accommodate real-world evidence and long-term outcome data. This change encourages manufacturers and health systems to co-develop evidence generation plans that demonstrate clinical and economic value. Supply chain and manufacturing strategies have shifted toward modularity and regionalization to reduce exposure to single-source disruptions and to accelerate time-to-market for software-enabled device updates. Patient expectations and digital engagement are also reshaping post-implant care: remote programming, telehealth follow-ups, and patient-reported outcome capture are accelerating adoption of hybrid care models. Collectively, these shifts are restructuring competitive dynamics and creating opportunities for strategic collaboration across clinical, technical, and commercial stakeholders.

A rigorous assessment of the cumulative impact of United States tariffs in 2025 on supply chains, component sourcing, procurement costs, and cross-border manufacturing for DBS devices

The introduction of tariffs in the United States in 2025 has exerted a multifaceted influence on the deep brain stimulation ecosystem, affecting cost structures, sourcing decisions, and the configuration of manufacturing footprints. Manufacturers reliant on cross-border supply of leads, implantable pulse generators, and ancillary components confronted increased input costs that necessitated reassessment of supplier relationships and inventory strategies. In response, some device producers accelerated diversification of their supply base and explored nearshoring options to mitigate exposure to trade policy volatility, while others absorbed short-term cost increases to sustain contractual pricing with health systems.

From a procurement perspective, hospitals and ambulatory surgical centers revisited device selection criteria to account for total cost of ownership, logistics complexity, and warranty or servicing arrangements. Group purchasing organizations and networked health systems intensified negotiations around long-term service contracts and spare-parts provisioning to manage operational risk. Regulatory and customs processing timelines also influenced lead times for new product introductions, prompting manufacturers to plan earlier submissions and engage in more proactive stakeholder communication. Over time, the tariff-driven adjustments reinforced the importance of resilient supply chain design, transparent cost modeling, and collaborative contracting between device suppliers and care providers.

A granular segmentation insight explaining how distinctions across technology, componentry, end-user settings, and distribution channels drive clinical adoption and commercial strategy in DBS

A granular segmentation perspective clarifies how technology choices, component architectures, clinical settings, and distribution models influence adoption dynamics and commercial strategy for DBS. Based on Technology, market is studied across Adaptive and Conventional. The Adaptive is further studied across Motion Feedback and Neural Feedback, which materially alters programming complexity, follow-up cadence, and evidence-generation requirements. Devices emphasizing motion feedback tend to prioritize integration with wearable and sensor platforms, whereas neural feedback solutions require more sophisticated signal processing and closed-loop validation to demonstrate clinical reliability.

Based on Component, market is studied across Extension, Implantable Pulse Generator, Lead, and Programmer, and each element carries distinct service, replacement, and regulatory considerations. Lead design evolution primarily influences targeting precision and chronic stability, while IPG advancements impact battery life, software capability, and remote-management features. Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, which differ in procedural volume, perioperative resources, and post-implant care pathways; high-volume tertiary centers often become centers of excellence that drive referral patterns, whereas specialty clinics may lead in long-term programming and follow-up. Based on Distribution Channel, market is studied across Direct Sales and Distribution Partner Networks, and these choices affect local clinical training, aftermarket service capability, and the speed of new technology adoption. Taken together, these segmentation lenses inform targeted go-to-market design, clinical evidence plans, and service delivery models that stakeholders should align with their strategic priorities.

A regionally focused analysis highlighting divergent regulatory environments, clinical adoption pathways, reimbursement landscapes, and competitive dynamics across major global markets

Regional dynamics create materially different pathways for clinical adoption, regulatory engagement, and commercial strategy across the global landscape. In the Americas, health systems increasingly focus on integrated care pathways, bundled procurement, and performance-based contracting; these priorities favor vendors that can demonstrate robust clinical governance support and predictable service models. Europe, Middle East & Africa present a heterogeneous regulatory and reimbursement environment, where country-level health technology assessment frameworks and procurement customs require localized evidence strategies and flexible commercial arrangements. In several markets within this region, public procurement cycles and reimbursement negotiation timelines dictate phased entry plans and partnerships with established local players. Asia-Pacific offers a contrasting mix of rapidly expanding neurosurgical capacity, public and private healthcare investment, and diverse regulatory pathways that reward agile market entry tactics and strategic alliances.

Across these regions, clinical practice patterns, device servicing models, and patient referral behaviors differ, influencing which provider types become early adopters and how post-implant care is organized. Stakeholders must therefore design regional strategies that balance global product consistency with local regulatory adaptation and tailored clinician engagement. This approach reduces launch friction and aligns evidence generation with payer needs in each geography.

A critical company-level evaluation of strategic priorities, R&D investments, partnership models, and go-to-market approaches that define competitive differentiation within the DBS landscape

Company-level strategies in the DBS sector reflect distinct choices about technology focus, partnership orchestration, and evidence development. Some firms have concentrated R&D on adaptive stimulation and closed-loop systems, prioritizing neural signal analytics and longer-term clinical validation to differentiate on clinical responsiveness. Others have invested in modular component systems that simplify upgrades and servicing, enabling incremental product enhancements without full-system replacement. Several companies emphasize integrated service models that combine device sales with training, remote-programming platforms, and structured follow-up pathways to reduce variation in outcomes and strengthen customer relationships.

Partnership plays are also prominent, with collaborations spanning imaging providers, software analytics companies, and rehabilitation service vendors to create end-to-end clinical solutions. Commercial tactics range from direct engagement with tertiary centers to alliances with distribution partners that provide localized clinical education and aftermarket support. Intellectual property strategies and regulatory submissions reflect these choices: companies investing heavily in adaptive algorithms often follow longer, data-rich regulatory pathways, while those emphasizing hardware refinements pursue iterative clearances. Investors and corporate development teams evaluating vendor capabilities should weigh the alignment between product roadmaps, clinical evidence commitments, and the operational demands of scaling across varied healthcare settings.

A prioritized set of actionable recommendations for industry leaders to accelerate clinical adoption, derisk supply chains, influence policy, and build durable commercial advantage in DBS

Industry leaders can pursue a set of pragmatic, prioritized actions to accelerate clinical adoption, strengthen supply resilience, and create durable commercial advantage in DBS. First, align device development and clinical evidence plans around measurable patient-centered outcomes and real-world performance metrics that resonate with payers and health systems. Second, invest in modular service architectures and training programs that reduce variability in implantation and programming, thereby improving consistency of outcomes across centers. Third, reassess supply chain design to incorporate dual sourcing, regional warehousing, and predictable spare-part provisioning that minimize exposure to trade policy shifts and logistical disruptions.

Fourth, cultivate collaborative relationships with centers of excellence, movement disorder neurologists, and rehabilitation providers to co-develop multicenter evidence and to accelerate diffusion of best practices. Fifth, adopt flexible commercial models that include outcome-based contracting, extended warranties, and bundled services to address evolving payer expectations. Finally, prioritize interoperability and software update pathways that allow devices to evolve post-implant with validated firmware and remote programming capabilities. Implementing these recommendations concurrently strengthens clinical credibility, reduces operational risk, and positions organizations to capitalize on emerging opportunities within integrated care ecosystems.

A transparent research methodology statement describing data collection, primary and secondary engagement, triangulation methods, and validation processes underpinning the DBS analysis

The research approach underlying this analysis combined primary and secondary methods, stakeholder engagement, and iterative validation to ensure robust, reproducible conclusions. Primary inputs included structured interviews with clinicians, procurement leaders, and device engineers, which provided qualitative insights into procedural workflows, evidence priorities, and operational constraints. Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, and device technical specifications to contextualize technological trends and safety performance. These data streams were triangulated to reconcile divergent perspectives and to highlight consistent patterns across clinical settings and geographies.

Analytical frameworks focused on capability mapping, supply chain vulnerability assessment, and clinical pathway integration. Validation cycles involved peer review by independent clinicians and industry experts to test the plausibility of inferred strategic implications. Where appropriate, scenario analysis was used to examine the consequences of policy shifts, technological milestones, or supply interruptions. Overall, the methodology emphasized transparency, reproducibility, and stakeholder relevance, ensuring that the insights are actionable for executive leaders, clinical program directors, and commercial teams seeking to navigate the evolving DBS landscape.

A concise synthesis of strategic takeaways, residual risks, innovation levers, and next-step considerations for stakeholders shaping the future trajectory of DBS in Parkinson's care

The conclusion synthesizes the strategic implications of technological innovation, shifting clinical practice, and evolving commercial dynamics for stakeholders engaged in deep brain stimulation. Advances in adaptive stimulation and closed-loop paradigms are setting new benchmarks for individualized therapy, but they also raise expectations for evidence generation, clinician training, and post-market surveillance. Meanwhile, supply chain and policy developments have underscored the necessity of resilient sourcing strategies and responsive commercial models. Therefore, organizations that integrate clinical program development, robust evidence plans, and flexible operational architectures will be best positioned to convert innovation into sustained clinical and commercial value.

Risk management remains central: procedural complexity, reimbursement uncertainty, and regulatory heterogeneity can all delay adoption or constrain market entry if unaddressed. Conversely, well-executed partnerships, targeted regional strategies, and investment in long-term outcome measurement create defensible differentiation. Ultimately, the path forward requires coordinated action across R&D, clinical engagement, supply chain design, and commercial execution to realize the full potential of DBS for patients with Parkinson's disease.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Emergence of closed-loop adaptive stimulation systems with real-time neural feedback
• 5.2. Expansion of directional lead technology for more precise targeting and symptom control
• 5.3. Integration of AI-driven programming algorithms to optimize patient-specific stimulation parameters
• 5.4. Development of minimally invasive stereotactic approaches with improved surgical accuracy
• 5.5. Growing adoption of rechargeable implantable pulse generators to reduce replacement surgeries
• 5.6. Advances in wireless telemetry for remote DBS device monitoring and noninvasive parameter adjustment
• 5.7. Increasing emphasis on personalized therapy protocols based on patient phenotype and biomarker profiles
• 5.8. Collaboration between neurotechnology companies and academic institutions for next-generation DBS research
• 5.9. Rising investments in disease-modifying neuromodulation paradigms targeting non-motor symptom relief
• 5.10. Regulatory approvals of novel electrode designs enabling multi-contact current steering capabilities

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Deep Brain Stimulation in Parkinson's Disease Market, by Technology

• 8.1. Adaptive
  • 8.1.1. Motion Feedback
  • 8.1.2. Neural Feedback
• 8.2. Conventional

9. Deep Brain Stimulation in Parkinson's Disease Market, by Component

• 9.1. Extension
• 9.2. Implantable Pulse Generator
• 9.3. Lead
• 9.4. Programmer

10. Deep Brain Stimulation in Parkinson's Disease Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Hospitals
• 10.3. Specialty Clinics

11. Deep Brain Stimulation in Parkinson's Disease Market, by Distribution Channel

• 11.1. Direct Sales
• 11.2. Distribution Partner Networks

12. Deep Brain Stimulation in Parkinson's Disease Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Deep Brain Stimulation in Parkinson's Disease Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Deep Brain Stimulation in Parkinson's Disease Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Medtronic plc
  • 15.3.2. Boston Scientific Corporation
  • 15.3.3. Abbott Laboratories
  • 15.3.4. Neurology Solutions
  • 15.3.5. Suzhou PINS Medical Co., Ltd.
  • 15.3.6. Aleva Neurotherapeutics SA
  • 15.3.7. Renishaw plc
  • 15.3.8. Newronika S.r.l.
  • 15.3.9. LivaNova, plc
  • 15.3.10. Inomed Medizintechnik GmbH

LIST OF FIGURES

• FIGURE 1. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY MOTION FEEDBACK, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY NEURAL FEEDBACK, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY EXTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY LEAD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY PROGRAMMER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION PARTNER NETWORKS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 96. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 97. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 99. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 101. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 103. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 105. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 106. AMERICAS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 107. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 110. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 111. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 112. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 113. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 114. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 115. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 116. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 117. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 118. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 119. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 122. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 123. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 124. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 125. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 126. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 127. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 128. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 129. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 130. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 137. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 138. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 139. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 140. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 141. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 142. EUROPE, MIDDLE EAST & AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 143. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 146. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 147. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 148. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 149. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 150. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 151. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 152. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 153. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 154. EUROPE DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 155. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 158. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 159. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 160. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 161. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 162. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 163. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 164. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 165. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 166. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 167. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 170. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 171. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 172. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 173. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 174. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 175. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 176. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 177. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 178. AFRICA DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 179. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 182. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 183. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 184. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 185. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 186. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 187. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 188. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 189. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 190. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 196. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 197. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 198. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 199. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 200. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 201. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 203. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 204. ASEAN DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 205. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 208. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 209. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 210. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 211. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 212. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 213. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 214. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 215. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 216. GCC DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 217. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 220. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 221. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 222. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 223. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 224. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 225. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 228. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 229. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 230. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 231. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 232. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 233. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 234. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 235. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 236. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 237. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 238. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 239. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 240. BRICS DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 241. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 244. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 245. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 246. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 247. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 248. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 249. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 252. G7 DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 253. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 256. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 257. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2018-2024 (USD MILLION)
• TABLE 258. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY ADAPTIVE, 2025-2032 (USD MILLION)
• TABLE 259. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 260. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
• TABLE 261. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 262. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 263. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 264. NATO DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 267. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 268. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 269. UNITED STATES DEEP BRAIN STIMULAT